Bristol Myers Squibb Company (NYSE:BMY) is one of the the most undervalued large-cap stocks to invest in now. On January 28, Piper Sandler raised its price target for Bristol Myers to $66 from $62, maintaining an overweight rating. The company noted that the stock remains undervalued as current prices largely account for Eliquis’ upcoming loss of exclusivity in the US and do not reflect improved visibility for a return to growth driven by continued pipeline progress.

A day earlier, Citi analyst Geoff Meacham raised the company’s price target on Bristol Myers to $60 from $53 with a neutral rating as part of a preview of the biopharma sector for the fourth quarter of 2025. Meacham suggested that improving estimates and a reduction in policy risks have set a favorable setup for the group heading into 2026.

Earlier on January 13, Leerink analyst David Risinger raised the company’s price objective for Bristol Myers Squibb Company (NYSE:BMY) to $60 from $54 with an outperform rating. The company sees significant upside potential for the stock in 2026, driven by a robust portfolio that currently appears heavily discounted by the market. After a company presentation on Jan. 12, Leerink noted that Bristol Myers expects 12 log data readings from eight different assets throughout 2026.

Bristol Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience and other areas.

While we recognize BMY’s potential as an investment, we believe some AI stocks offer greater upside potential and less downside risk. If you’re looking for an extremely undervalued AI stock that will also benefit significantly from Trump-era tariffs and the onshoring trend, check out our free report on the best short term AI stock.

READ THE FOLLOWING: 30 stocks that should double in 3 years i 11 Hidden AI Stocks to Buy Right Now.

Disclosure: no. This article is originally published in Monkey Insider.